MEKTOVI 15 MG — DIN 02513080
BINIMETINIB : 15 MG · PFIZER CANADA ULC · TABLET · wholesale supply in Canada
Health Canada status: MARKETED
What is MEKTOVI?
MEKTOVI 15 MG contains BINIMETINIB : 15 MG. It is listed in the Health Canada Drug Product Database under DIN 02513080, held by PFIZER CANADA ULC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 05-Jul-2021. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is MEKTOVI used for?
MEKTOVI (binimetinib) is indicated, in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation, as detected by a validated test. Clinical data supporting the use of MEKTOVI in the treatment of patients with BRAF V600 mutations are limited to patients with V600E or V600K mutations.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Binimetinib cost around the world?
Binimetinib is listed on 13 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Austria publishes a KVP (Kassenverkaufspreis); Bahrain publishes a retail (max). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Austria | KVP (Kassenverkaufspreis) | 2 | 4 | EUR███.██ |
| Norway | max AUP (pharmacy retail) | 1 | 4 | NOK███.██ |
| Australia | ex-manufacturer | 1 | 2 | AUD███.██ |
| Czechia | max producer price (ex-factory) | 1 | 2 | CZK███.██ |
| Italy | ex-factory (classe H) | 2 | 2 | EUR███.██ |
| Luxembourg | reimbursement | 2 | 2 | EUR███.██ |
| United Arab Emirates | public | 1 | 1 | AED███.██ |
| Bahrain | retail (max) | 1 | 1 | BHD███.██ |
| Hungary | producer price (ex-factory) | 1 | 1 | HUF███.██ |
| Iceland | max wholesale | 1 | 1 | ISK███.██ |
| Romania | max producer price | 1 | 1 | RON███.██ |
| Saudi Arabia | public | 1 | 1 | SAR███.██ |
| Slovakia | categorised final price | 1 | 1 | EUR███.██ |
23 pack listings across 16 brand entries and 12 price bases, refreshed 08 Sep 2026. Ranges span every Binimetinib pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 15 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Pack configuration (monograph) | Yellow/dark yellow, unscored biconvex oval film-coated tablets debossed with a stylized “A” on one side and "15" on the other side. Supplied in bottles containing 90 or 180 tablets. |
| Storage | Store between 15-30°C. Keep out of reach and sight of children. |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Binimetinib |
|---|---|
| ATC code | L01EE03 |
| AHFS class | 10:00.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02513080 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2513080 |
| Brand name | MEKTOVI |
| Generic / active ingredient | BINIMETINIB : 15 MG |
| Market authorization holder | PFIZER CANADA ULC |
| Health Canada schedule | Prescription |
| ATC code | L01EE03 |
| ATC anatomical main group | L — Antineoplastic and immunomodulating agents |
| ATC therapeutic subgroup | L01EE |
| Current status | MARKETED |
| Status date | 05-Jul-2021 |
| Original market date | 2021-07-05 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
The recommended dosage of MEKTOVI is 45 mg (three 15 mg tablets) orally taken twice daily, approximately 12 hours apart, in combination with encorafenib until disease progression or unacceptable toxicity. MEKTOVI may be taken with or without food. If a dose of MEKTOVI is missed, it should not be taken if it is less than 6 hours of the next dose of MEKTOVI. Do not take an additional dose if vomiting occurs after MEKTOVI administration but continue with the next scheduled dose.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
MEKTOVI (binimetinib) is contraindicated in patients who are hypersensitive to this drug or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container.
Warnings and precautions
Serious Warnings and Precautions Box: • Left ventricular dysfunction (see 7 WARNINGS AND PRECAUTIONS; Cardiovascular) • Venous thromboembolism (see 7 WARNINGS AND PRECAUTIONS; Cardiovascular) • Major hemorrhagic events (see 7 WARNINGS AND PRECAUTIONS; Hematologic) • Retinal pigment epithelial detachment and retinal vein occlusion (see 7 WARNINGS AND PRECAUTIONS; Ophthalmologic) • Interstitial lung disease (see 7 WARNINGS AND PRECAUTIONS; Respiratory) • Rhabdomyolysis (see 7 WARNINGS AND PRECAUTIONS; Rhabdomyolysis) General Warnings: MEKTOVI (binimetinib) is indicated for use in combination with encorafenib. For additional information on warnings and precautions associated with encorafenib treatment, consult encorafenib Product Monograph. Confirmation of BRAF V600 mutation using a validated test is required for selection of patients appropriate for treatment with MEKTOVI. Cardiovascular: Hypertension, or worsening of pre-existing hypertension, can occur with the use of binimetinib. Blood pressure should be measured at baseline and monitored during treatment, with control of hypertension by standard therapy as appropriate. In case of severe hypertension, temporary interruption of binimetinib is recommended until hypertension is controlled. Cardiomyopathy, manifesting as left ventricular dysfunction associated with symptomatic or asymptomatic decreases in ejection fraction, has been reported in patients treated with MEKTOVI in combination with encorafenib. Assess ejection fraction by echocardiogram or MUGA scan prior to initiating treatment, one month after initiating treatment, and then every 2 to 3 months during treatment. The safety of MEKTOVI in combination with encorafenib has not been established in patients with a baseline ejection fraction that is either below 50% or below the institutional lower limit of normal (LLN). Patients with cardiovascular risk factors should be monitored closely when treated with MEKTOVI. Venous thromboembolism (VTE): Venous thromboembolism (VTE) occurred in 6% of patients receiving MEKTOVI in combination with encorafenib, including 3.1% of patients who developed pulmonary embolism. Hematologic: Hemorrhage can occur when MEKTOVI is administered in combination with encorafenib. In COLUMBUS, hemorrhage occurred in 19% of patients receiving MEKTOVI in combination with encorafenib; Grade 3 or greater hemorrhage occurred in 3.2% of patients. The most frequent hemorrhagic events were gastrointestinal, including rectal hemorrhage (4.2%), hematochezia (3.1%), and hemorrhoidal hemorrhage (1%). Events of hematuria occurred in 2.6%. Fatal cerebral hemorrhage in the setting of new or progressive brain metastases occurred in 1.6% of patients. Hepatic: Hepatotoxicity can occur when MEKTOVI is administered in combination with encorafenib. Monitor liver laboratory tests before initiation of MEKTOVI, monthly during treatment, and as clinically indicated. Musculoskeletal: Rhabdomyolysis can occur when MEKTOVI is administered in combination with encorafenib. Monitor CPK and creatinine levels prior to initiating MEKTOVI, periodically during treatment, and as clinically indicated. Ophthalmologic: Serous Retinopathy occurred in 20% of patients treated with MEKTOVI in combination with encorafenib; 8% were retinal detachment and 6% were macular edema. Patients should be assessed at each visit for symptoms of new or worsening visual disturbances. If symptoms of new or worsening visual disturbances including diminished central vision, blurred vision or loss of vision are identified, a prompt ophthalmologic examination is recommended. Retinal Vein Occlusion (RVO) is a known class-related adverse reaction of MEK inhibitors and may occur in patients treated with MEKTOVI in combination with encorafenib. The safety of MEKTOVI has not been established in patients with a history of RVO or current risk factors for RVO including uncontrolled glaucoma or a history of hyperviscosity or hypercoagulability syndromes. Perform op
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
2 · Same class — other molecules in ATC L01EE
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Trametinib | MEKINIST | 4 | 3 | Yes |
| Selumetinib | KOSELUGO | 2 | 2 | Yes |
| Binimetinib | MEKTOVI | 1 | 1 | Yes |
| Cobimetinib | COTELLIC | 1 | 1 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC L01E
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| L01EX | Avapritinib · Cabozantinib · Capivasertib · Capmatinib · Entrectinib · +17 more | 80 | 64 |
| L01EA | Asciminib · Bosutinib · Dasatinib · Imatinib · Nilotinib · +1 more | 73 | 57 |
| L01EB | Afatinib · Dacomitinib · Erlotinib · Gefitinib · Lazertinib · +1 more | 40 | 23 |
| L01EF | Abemaciclib · Palbociclib · Ribociclib | 17 | 14 |
| L01ED | Alectinib · Brigatinib · Ceritinib · Crizotinib · Lorlatinib | 10 | 10 |
| L01EJ | Fedratinib · Momelotinib · Ruxolitinib | 8 | 8 |
| L01EN | Erdafitinib · Infigratinib · Pemigatinib | 11 | 6 |
| L01EC | Dabrafenib · Encorafenib · Vemurafenib | 5 | 5 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is MEKTOVI called?
Also recorded in Canada as: binimetinib 15 MG Oral Tablet [Mektovi] (US), binimetinib 15 MG Oral Tablet (US), BINIMETINIB (US), BINIMETINIB (GLOBAL), BINIMETINIB (UK).
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.